Data show many patients discontinue or switch treatment within the first year ...

BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — ...

The picture on this rare condition has been getting clearer ...

Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data ...

October 17, 2012 (Boston, Massachusetts) — The risk of the potentially life-threatening side effect angioedema differs between different classes of drugs that inhibit the renin-angiotensin-aldosterone ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of severe swelling throughout your body. It is caused by abnormal immune responses. But unlike allergic swelling, HAE is not ...

New York, USA, May 06, 2025 (GLOBE NEWSWIRE) -- Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses ...

Angioedema is basically swelling of the deeper layers of the skin. This is due to accumulation of fluids caused by an allergic reaction. Pathogenesis of the types of angioedema has been studied ...

Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and the ...

Intellia Therapeutics released positive Phase 3 trial results for its lonvo-z treatment for hereditary angioedema, saying it met primary and all key secondary endpoints. The company said it began a ...